title: Dietary (n-3) fatty acids reduce plasma F2-isoprostanes but not prostaglandin F2alpha in healthy humans.
abstract: (n-3) Fatty acids are unsaturated and are therefore easily subject to oxidization; however, they have several beneficial health effects, which include protection against cardiovascular diseases. The aim of this study was to investigate whether (n-3) fatty acids, with a controlled fat quality in the background diet, affect nonenzymatic and enzymatic lipid peroxidation and antioxidant status in humans. A total of 162 men and women in a multicenter study (The KANWU study) were randomly assigned to a diet containing a high proportion of saturated fatty acids or monounsaturated fatty acids (MUFA) for 3 mo. Within each diet group, there was a second random assignment to supplementation with fish-oil capsules [3.6 g (n-3) fatty acids/d] or placebo. Biomarkers of nonenzymatic and enzymatic lipid peroxidation in vivo were determined by measuring 8-iso-prostaglandin F(2alpha) (8-iso-PGF(2alpha)) and prostaglandin F(2alpha) (PGF(2alpha)) concentrations in plasma at baseline and after 3 mo. Antioxidant status was determined by measuring plasma antioxidant capacity with an enhanced chemiluminescence assay. The plasma 8-iso-PGF(2alpha) concentration was significantly decreased after 3 mo of supplementation with (n-3) fatty acids (P = 0.015), whereas the PGF(2alpha) concentration was not affected. The antioxidant status was not affected by supplementation of (n-3) fatty acids, but was improved by the background diet with a high proportion of MUFA. We conclude that supplementation with (n-3) fatty acids decreases nonenzymatic free radical-catalyzed isoprostane formation, but does not affect cyclooxygenase-mediated prostaglandin formation.
authors.affiliation: The KANWU Study Group at Clinical Nutrition and Metabolism, Department of Public Health and Caring Sciences, Uppsala University, Sweden. cecilia.nalsen@pubcare.uu.se
authors.forename: Cecilia
authors.initials: C
authors.lastname: Nälsén
authors.forename: Bengt
authors.initials: B
authors.lastname: Vessby
authors.forename: Lars
authors.initials: L
authors.lastname: Berglund
authors.forename: Matti
authors.initials: M
authors.lastname: Uusitupa
authors.forename: Kjeld
authors.initials: K
authors.lastname: Hermansen
authors.forename: Gabrielle
authors.initials: G
authors.lastname: Riccardi
authors.forename: Angela
authors.initials: A
authors.lastname: Rivellese
authors.forename: Len
authors.initials: L
authors.lastname: Storlien
authors.forename: Arja
authors.initials: A
authors.lastname: Erkkilä
authors.forename: Seppo
authors.initials: S
authors.lastname: Ylä-Herttuala
authors.forename: Linda
authors.initials: L
authors.lastname: Tapsell
authors.forename: Samar
authors.initials: S
authors.lastname: Basu
mesh_terms: D000284:Administration, Oral; D004032:Diet; D015237:Dinoprost / Q000097:blood*; D002149:Energy Intake; D028441:F2-Isoprostanes / Q000097:blood*; D005227:Fatty Acids / Q000008:administration & dosage / Q000494:pharmacology; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D012016:Reference Values
chemical_list: D028441:F2-Isoprostanes; D005227:Fatty Acids; D015525:Fatty Acids, Omega-3; D015237:Dinoprost